Last checked at 14 Feb 2018 17:26
N4 Pharma Plc
("N4 Pharma" or the "Company")
Exercise of Warrants and Total Voting Rights
The Company announces that it has received an exercise notice for the exercise of 394,328 warrants over ordinary shares of 0.4p each at an exercise price of 8.5 pence per warrant ("New Ordinary Shares"). Application has been made for admission of 394,328 New Ordinary Shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on 16 February 2018.
Following Admission, there will be a total of 87,723,751 ordinary shares in issue. Shareholders should use the figure of 87,723,751 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure and Transparency Rules.
Enquiries:
N4 Pharma CEO, Nigel Theobald |
Via Alma PR |
Stockdale Securities Tom Griffiths |
Tel: +44(0)207 601 6100 |
Beaufort Securities Elliot Hance |
Tel: +44(0)207 382 8300 |
Alma PR Josh Royston Robyn Fisher |
Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.
N4 Pharma's reformulation work falls under two divisions:
• generic, already commercialised, drugs; and
• delivery of novel and existing vaccines.
N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.
N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.
N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.